Back to Browse Journals » Infection and Drug Resistance » Volume 4

Review of oral cholera vaccines: efficacy in young children

Authors Masuet Aumatell C, Ramon Torrell JM, Zuckerman JN

Published Date September 2011 Volume 2011:4 Pages 155—160


Published 14 September 2011

Cristina Masuet Aumatell1, JM Ramon Torrell1, Jane N Zuckerman2
1International Health Centre, Preventive Medicine Department, Bellvitge Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; 2World Health Organization Collaborating Centre for Reference, Research and Training in Travel Medicine, University College London Medical School, London, UK

Background: Young children are one of the most vulnerable groups who may be infected with cholera. The following literature review of the efficacy of the currently available cholera vaccines provides a clear evidence base for the clinical administration of cholera vaccine, particularly in an epidemic situation.
Aim: To assess the efficacy of oral cholera vaccines in preventing cases of cholera in young children.
Methods: A systematic literature review was undertaken for the period 1983 to 2011 using PubMed and the search terms “oral cholera vaccines,” “children,” and “efficacy,” limited to “clinical trials” and “human studies”.
Results: Oral cholera vaccine provides an acceptable level of protection in young children, with the level of protection being greater at 12 or 24 months following immunization.
Conclusions: Children exposed to a potential risk of cholera are recommended to be vaccinated with an oral cholera vaccine, irrespective of whether its constituents include the B subunit.

Keywords: efficacy, oral cholera vaccine, children

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance

Chen LF, Anderson DJ, Paterson DL

Infection and Drug Resistance 2012, 5:133-141

Published Date: 24 September 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011